Principal Investigators Launches Website for Clinical Trial and Patient Referral Offers
Principal Investigators announced global availability of its online platform designed specifically to connect Medical Doctors with Pharma and R&D companies involved in clinical studies
Principal Investigators® (www.principalinvestigators.com) announced the global availability of its online platform designed specifically to connect Medical Doctors with Pharma and R&D companies involved in clinical studies. With principalinvestigators.com medical doctors can create a profile and start referring their patients and increase their ability to start a new clinical trial at their site. It allows Pharma & CRO companies to locate investigators from all over the globe and carry out feasibility all in one place. Investigators also can monitor offers, apply to trials within their area of expertise and gain new business.
Read the full release here.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
